Welcome to our dedicated page for Sinovac Biotech news (Ticker: SVA), a resource for investors and traders seeking the latest updates and insights on Sinovac Biotech stock.
Sinovac Biotech Ltd (SVA) is a leading biopharmaceutical company focused on developing vaccines for infectious diseases including hepatitis, influenza, and COVID-19. This page provides investors and healthcare professionals with centralized access to official company announcements, financial disclosures, and operational updates.
Track critical developments through verified press releases covering clinical trial results, regulatory approvals, and manufacturing expansions. Our curated news collection includes earnings reports, partnership announcements, and analysis of Sinovac's role in global immunization programs.
Key content categories include vaccine research updates, government collaboration news, and financial performance reports. Bookmark this page for real-time insights into Sinovac's progress in addressing public health challenges through innovative biopharmaceutical solutions.
Sinovac (NASDAQ: SVA) said the Antigua High Court updated an interlocutory order naming ten directors to comprise the Company board until the trial listed in late April/early May 2026, and noted that Rui-Ping Xiao resigned for personal reasons. The Company also announced the Audit Committee approved engagement of Zhonghua as independent auditor effective December 31, 2025. Zhonghua is registered in China and with the PCAOB, and its engagement supersedes UHY LLP.
The company said seven of nine board members are independent and all Audit, Compensation and Nominating & Corporate Governance committee members are independent.
Sinovac (NASDAQ: SVA) received a Nasdaq notification dated January 2, 2026 saying the company was not in compliance with Nasdaq Listing Rule 5250(c)(2) after failing to timely file a Form 6-K containing an interim balance sheet and income statement for the second quarter of 2025.
As previously disclosed, Nasdaq issued a delisting determination in November 2025; the company requested a hearing on November 19, 2025. Nasdaq informed Sinovac the Nasdaq Hearings Panel will consider the late‑filing notice at a hearing scheduled for January 8, 2026, where Sinovac has been invited to present its plan and views aimed at maintaining its Nasdaq listing.
Sinovac (NASDAQ: SVA) announced that the Antigua High Court made an interim order appointing eight directors as the Company's Board until the trial of a disputed Special Shareholders Meeting, now listed for late April/early May 2026. The court hearing occurred on 27 October 2025, and the dispute concerns the outcome of the 8 July 2025 Special Shareholders Meeting.
A Board meeting on 17 December 2025 reaffirmed commitment to shareholder value, to complete the audit with the Audit Committee, to work with management and advisors, to seek restoration of NASDAQ trading, and to pursue negotiated resolutions among parties.
Sinovac (Nasdaq: SVA) received a delisting determination from Nasdaq on November 12, 2025 for non-compliance with Nasdaq Listing Rule 5250(c)(1) after failing to timely file its Form 20-F for the year ended December 31, 2024 by the extension deadline of November 11, 2025.
The company previously disclosed Grant Thornton Zhitong's resignation on April 15, 2025, engaged UHY LLP as its new independent registered public accounting firm on October 24, 2025, and intends to request a hearing with the Nasdaq Hearing Panel on or before November 19, 2025 to appeal the Staff Determination and seek stays of any suspension or delisting while UHY completes the audit.
SINOVAC (NASDAQ: SVA) announced that its Audit Committee approved the engagement of UHY LLP as the company’s independent auditor, effective October 24, 2025. UHY will audit SINOVAC’s financial statements for the years ended Dec 31, 2021–2025, perform internal control audits as of Dec 31, 2024 and 2025, and conduct interim reviews for the six-month periods ended June 30, 2024 and 2025.
The company said it plans to file Form 20-Fs and Form 6-Ks as soon as practicable to meet SEC and NASDAQ compliance requirements, and described the appointment as a critical step toward improved transparency and the aim of resuming trading on NASDAQ Beijing.
SINOVAC Biotech (NASDAQ: SVA) has issued a statement regarding its July 8, 2025 Special Meeting of Shareholders, which was validly adjourned by Chairman Chiang Li due to pending litigation in Antigua concerning disputed PIPE shares. The company is addressing unauthorized actions by SAIF and the Dissenting Investor Group, who allegedly conducted an invalid meeting after the official adjournment.
The current Board, led by Dr. Chiang Li, maintains its authority and continues to execute key priorities, including: dividend distributions, a special cash dividend of $55.00 per share, working towards NASDAQ trading resumption, appointing a new auditor, and exploring a potential Hong Kong Stock Exchange listing.
The Special Meeting will be reconvened once the Antigua court makes a final decision on the validity of the PIPE shares issued to Advantech/Prime and Vivo Capital.
Sinovac Biotech (NASDAQ: SVA) announced the first meeting of its newly elected Board of Directors following the July 8, 2025 Special Meeting. The new board was elected with 33,248,861 votes (54.71%) of total votes. Mr. Andrew Y. Yan, Managing Partner of SAIF Partners, was elected as Chairman of the Board.
The Board outlined key priorities including exploring future dividend plans, appointing a new auditor to resume NASDAQ trading, resolving ongoing shareholder litigations, and restoring stable operations. The Board confirmed Mr. Yin Weidong will continue as Executive Director and CEO of the company.
SINOVAC Biotech (NASDAQ: SVA) strongly denounces recent claims made by SAIF and the Imposter Former Board regarding a Special Meeting of Shareholders. The company's Chairman Chiang Li validly adjourned the July 8, 2025 meeting pending litigation resolution in Antigua concerning 11.8 million disputed PIPE shares issued to the Dissenting Investor Group.
According to Georgeson, SINOVAC's proxy solicitor, the company's White Proxy Card received strong support from valid shareholders before the adjournment. The current Board maintains it is the only legitimate governing body and accuses SAIF of conducting unauthorized vote tallying and making illegal claims about reconvening the meeting.
The company is evaluating legal remedies against SAIF and the Imposter Former Board in both Antigua and the United States while working to implement the UK Privy Council's judgment regarding the PIPE shares validity.
SINOVAC Biotech (NASDAQ: SVA) has announced the distribution process of its previously declared US$55.00 per common share special cash dividend to shareholders of record as of July 7, 2025. The payment process varies based on shareholding type:
For record holders with amounts under US$100 million, dividend checks will be sent via FedEx/UPS on July 9, 2025. Larger amounts will be wire transferred. Shareholders holding shares through brokers will receive payments once their brokers submit the required broker letter to the Paying Agent, with distributions beginning July 9, 2025.
FAQ
What is the market cap of Sinovac Biotech (SVA)?
